5 Best Tech Stocks To Watch Right Now

The U.S. Department of Defense wrapped up the workweek Friday with the announcement of nine new contracts, worth more than $791 million in total. One single contract, however, accounted for fully 62% of the funds on offer.

The winners of that contract, a $494 million firm-fixed-price, multiple-award, task-order contract for the supply of hardware, software, and related integration services needed for the U.S. Army's "Information Technology Enterprise Solution-2" (ITES-2S) enterprise business systems project, include:

Dell's (NASDAQ: DELL  ) Federal Systems business International Business Machines (NYSE: IBM  ) And four privately owned companies -- Unicom Government, CDW Government, Iron Bow Technologies, and World Wide Technology.

The specific type of contract being awarded is best described as an "umbrella" contract, setting a maximum amount of funds that can be spent (the $494 million). Dell, IBM, and the other contract winners will now need to bid against each other to sell the Army equipment and software in response to specific task orders, up until said ceiling value has been reached.

5 Best Tech Stocks To Watch Right Now: Garmin Ltd.(GRMN)

Garmin Ltd., together with its subsidiaries, designs, develops, manufactures, and markets global positioning system (GPS) enabled products and other navigation, communication, and information products for the automotive/mobile, outdoor, fitness, marine, and general aviation markets worldwide. The company offers a range of automotive navigation products, and various products and applications designed for the mobile GPS market; GPS enabled handheld products for hunters, hikers, geocachers, outdoors enthusiasts, cyclists, and golfers; dog tracking systems; tracker systems; and training assistants for athletes. It also provides handhelds, network products and multifunction displays, fixed-mount GPS/chartplotter products, instruments, fish finders, radars, autopilots, VHF radios, marine networking products, and sounder products. In addition, the company offers GPS-enabled navigation, VHF communications transmitters/receivers, multi-function displays, electronic flight instrumen tation systems, automatic flight control systems, traffic advisory systems and traffic collision avoidance systems, terrain awareness and warning systems, instrument landing system receivers, surveillance products, audio panels, and cockpit datalink systems. The company?s sells its products through a network of independent dealers and distributors, as well as through original equipment manufacturers. Garmin Ltd. was founded in 1990 and is based in Schaffhausen, Switzerland.

Advisors' Opinion:

• [By Sean Williams]

  Stateside, Garmin (NASDAQ: GRMN  ) is seeing many of the issues I project AutoNavi will soon encounter. With mobile coverage spreading into many rural areas, many smartphones and tablets are now able to deliver the same navigation quality and features that Garmin's and AutoNavi's products bring to the table. Understandably, China's wireless infrastructure isn't as developed as what we have here in the U.S., so the lifespan of AutoNavi's products will be extended compared to Garmin, which has been on a multiyear downswing. Ultimately, though, the same product replacement cycle is going to hit AutoNavi when China's wireless infrastructure improves, and will slowly erode its business.

• [By Eric Volkman]

  Garmin (NASDAQ: GRMN  ) has chosen a fixed spot on its map and pinned four dividend payments to it. In accordance with Swiss corporate law, the company's shareholders have approved a full year of quarterly distributions. Each will total $0.45 per share. The first will be paid on June 28 to shareholders of record as of June 18. The payment and record dates for the following three disbursements are Sept. 30 and Sept. 16, Dec. 31 and Dec. 16, and March 31 and March 17, 2014, respectively.

• [By Laura Brodbeck]

  Wednesday

  Earnings Expected From: Marriott International (NYSE: MAR), MetLife, Inc. (NYSE: MET), Facebook, Inc. (NASDAQ: FB), Garmin Ltd (NASDAQ: GRMN), Ryland Group, Inc. (NYSE: RYL) Economic Releases Expected: British consumer confidence, New Zealand Interest rate decision, US FOMC meeting announcement, German CPI, US GPD, US core CPI, US nonfarm employment change

  Thursday

5 Best Tech Stocks To Watch Right Now: Portugal Telecom SGPS S.A .(PT)

Portugal Telecom, SGPS, S.A., together with its subsidiaries, provides telecommunications services in Portugal, Brazil, sub-Saharan Africa, and Asia. It offers fixed line telephone, Internet protocol television, and direct-to-home satellite pay-TV services; and mobile telecommunications services, such as voice, data, and Internet-related multi-media services primarily for mobile phones, smart phones, tablets, and laptops. The company also provides enterprise services, including data and business solutions, as well as information technology/information system and business process outsourcing services. In addition, it provides engineering solutions and training services in telecommunications; postal network services; consultant negotiation services; public telecommunication services and telebroadcasting services; call center services; mobile cellular services; and development and consultancy services in the areas of electronic commerce, contents, telecommunications, and info rmation technology. Further, it engages in the purchase, management, administration, sale, and investment consultancy of real estate properties; business advisory board service installment, consultation, administration, and business management; and pension fund management,. Additionally, the company provides wholesale services comprising leased lines, interconnection, unbundled access to its local loops, broadband asymmetric digital subscriber line (ADSL), wholesale line rental, access to ducts, transmission of television and radio signals, and international carrier services. The company also publishes directories; provides portal services; and sells telecommunications equipment. As of December 31, 2010, it had approximately 4.9 million telephone and ADSL access lines in service. The company was formerly known as Portugal Telecom, SA and changed its name to Portugal Telecom, SGPS, S.A. in December 2000. Portugal Telecom, SGPS, S.A. was founded in 1994 and is based in Lisbon, Portugal.

Advisors' Opinion:

• [By Brian Pacampara]

  Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, telecommunications company Portugal Telecom (NYSE: PT  ) has earned a coveted five-star ranking.

10 Best Canadian Stocks To Invest In Right Now: Orbit International Corporation(ORBT)

Orbit International Corp., through its subsidiaries, engages in the design, manufacture, and sale of electronic components and subsystems, and commercial and custom power units. The company operates through two segments, Electronics and Power. The Electronics segment designs, manufactures, and sells customized panels, components, and subsystems for contract program requirements to prime contractors, governmental procurement agencies, and research and development laboratories. Its products include remote control units; intercommunication panels; displays; keyboards, keypads, and pointing devices; operator control trays; command display units; gun computer system cabinets; gun mount control panels; serial data converters; harness assemblies; and system integration products. This segment?s products are deployed in surveillance aircraft, shipboard programs, and land-based guidance control programs. This segment also performs the analysis and evaluation of caliber naval gun we apon systems performance; involves in the design, integration, and production of components for caliber naval gun weapon systems; and offers engineering supplies and services in support of caliber naval gun weapon systems initiatives. The Power segment designs, manufactures, and sells power supplies, AC power sources, frequency converters, uninterruptible power supplies, and associated analytical equipment and other electronic equipment, as well as commercial-off-the-shelf power modules. This segment?s products are used in production lines, engineering labs, oil and gas exploration, aircraft and ships, and related ground support systems. The company markets its products primarily through its direct sales personnel, as well as through manufacturer's representatives and distributors. The company was formerly known as Orbit Instrument Corp. and changed its name to Orbit International Corp. in July 1991. Orbit International Corp. was founded in 1957 and is based in Hauppauge, N ew York.

5 Best Tech Stocks To Watch Right Now: Cell Therapeutics Inc (CTIC)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company�� research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisition gaining worldwide rights to S*BIO Pte Ltd.'s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin�� lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company�� EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed complete response compared to patients treated with standard chem! otherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company�� biologically-enhanced chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces responsiveness to TMZ. A phase I/II study of OPAXIO combined with radi! otherapy ! and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma�� drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic syndrome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik, I! nc., TEVA! Pharmaceuticals Industries Ltd. and PharmaMar.

Advisors' Opinion:

• [By Nathalie Tadena]

  Among the companies with shares expected to actively trade in Friday’s session are Vanda Pharmaceuticals Inc.(VNDA), Kimberly-Clark(KMB) and Cell Therapeutics(CTIC).

• [By John Udovich]

  Large and small cap cancer stocks Gilead Sciences, Inc (NASDAQ: GILD), Celgene Corporation (NASDAQ: CELG), Veracyte (NASDAQ: VCYT), Genomic Health, Inc (NASDAQ: GHDX), Cell Therapeutics Inc (NASDAQ: CTIC) and MetaStat Inc (OTCMKTS: MTST) have all been producing a steady stream of news lately for biotech investors looking for a way to cash in on the growth in development of�cancer treatments. Just consider the following news:

• [By Bryan Murphy]

  If you're reading this, then odds are you already know that the last two weeks (not even a full two weeks) have been more fruitful for Cell Therapeutics Inc. (NASDAQ:CTIC) shareholders than the prior two years have been - the stock's up 28% since last Thursday. And, odds are you already know why. The question most of you are asking now is, can CTIC actually keep climbing at this pace, or even keep climbing at any pace? The answer is "yes", though floating that answer almost inherently requires a deeper explanation.

5 Best Tech Stocks To Watch Right Now: Tucows Inc Com Npv (TC.TO)

Tucows Inc. distributes Internet services worldwide. The company offers domain name registration, and security and identity products through digital certificates, email, and mobile telephony services. It provides OpenSRS, a wholesale service, which manages domain names, mailboxes, and digital certificates through a network of approximately 11,000 Web hosts, Internet service providers (ISPs), and other resellers; Platypus, a billing service that provides ISPs with an industry-specific solution for billing, service provisioning, and customer account management; and Hover, a retail service, which offers domain names, mailboxes, and digital certificates management services for consumers and small businesses. In addition, the company offers YummyNames that manages various domain names with a portfolio of approximately 42,000 domains; and Butterscotch, a content service, which operates butterscotch.com and tucows.com advertising-supported Websites that provide content in the for m of approximately 4,000 videos and 385,000 software and mobile listings, and articles. The company was formerly known as Infonautics, Inc. and changed its name to Tucows Inc. in August 2001. Tucows Inc. was founded in 1992 and is headquartered in Toronto, Canada.